How to Choose an Insights Management Platform for Pharma: 6 Criteria

The single most important criterion is whether the platform was built exclusively for pharmaceutical and life sciences workflows — or whether it is a generic tool that has been adapted, bolted on, or rebranded for medical affairs use.

What to look for:

• Does the platform natively understand pharmaceutical taxonomy, disease states, and medical affairs workflows?
• Was it designed specifically for MSLs, medical affairs leadership, and KOL management — or for commercial sales teams?
• Does the vendor have deep life sciences domain expertise in product development, not just consulting?
• Is the platform used by global tier-1 pharmaceutical companies — not just SMBs or non-pharma industries?

Red flags:

• Platform originally built for sales CRM or market research, with a “pharma module” added later
• Generic AI models with no pharmaceutical vocabulary training
• No evidence of deployment by major pharma companies

Medical affairs intelligence does not come from a single channel. An effective insights management platform must aggregate intelligence from every source your teams operate — not just MSL field notes.

Required capture channels:

• MSL field interactions with HCPs and KOLs (free text, voice, guided surveys)
• Advisory board and scientific exchange programmes
• Medical congresses — pre-event intelligence and real-time floor capture
• Medical information line queries from HCPs and patients
• Scientific publications and clinical literature monitoring
• Social listening from digital medical communities

Why it matters: Platforms that only capture field notes miss the 60–70% of medical intelligence generated through non-MSL channels. Cross-channel triangulation — identifying the same insight across MSL notes, congress presentations, and advisory board discussions — is impossible without aggregated omnichannel data.

AI is a core requirement for modern insights management — but not all AI is equal in a pharmaceutical context. Generic natural language processing (NLP) models misinterpret medical terminology, drug names, clinical trial phases, and scientific sentiment with alarming frequency.

What to evaluate:

• Is the AI trained on biomedical ontologies and pharmaceutical vocabulary — not general consumer text?
• Does auto-tagging work accurately on clinical language, therapy area terminology, and drug names?
• Can sentiment analysis distinguish between scientific enthusiasm, clinical concern, and commercial interest?
• Does the AI identify cross-channel trends and triangulate insights from multiple sources?
• Are AI-generated reports explainable and auditable — not black-box outputs?

In pharmaceutical organisations, compliance is not a feature — it is a fundamental requirement. Data flowing through an insights management platform carries significant regulatory, legal, and ethical risk if handled incorrectly.

Non-negotiable compliance requirements:

• Medical/commercial firewall: Strict data separation between medical affairs and commercial/marketing teams
• Adverse event detection: Automatic flagging and escalation of potential adverse events or off-label mentions
• Regulatory standards: Full alignment with GDPR, HIPAA, SOC2, and 21 CFR Part 11
• Sensitive-term flagging: Automated detection of predefined sensitive terminology with mandatory review workflows
• Granular permissions: Role-based access controls ensuring each user sees only the data appropriate to their function
• Audit trails: Complete, immutable records of who accessed, edited, or escalated insights

The best insights management platform is one your teams will actually use. Any solution that requires MSLs to abandon Veeva, duplicate data entry, or work outside their existing workflow will face adoption failure — regardless of its analytical capabilities.

Integration requirements:

• CRM: Native API integration with Veeva CRM and/or Salesforce — pulling interaction context automatically, eliminating duplicate entry
• BI Tools: Seamless export and connection to Power BI and Tableau for cross-functional executive dashboards
• SSO & Identity: Single sign-on compatibility with enterprise identity providers (Azure AD, Okta, etc.)
• Data governance: Compatibility with your organisation’s data lake or enterprise data warehouse architecture

Ask vendors: “Can an MSL who currently uses Veeva start using your platform without any change to their Veeva workflow?” The answer should be yes.

The final — and often most overlooked — criterion separates data repositories from true intelligence platforms. Capturing insights is only half the value. The platform must close the loop: converting insights into decisions, tracking those decisions to outcomes, and enabling medical affairs leadership to demonstrate the function’s strategic ROI.

What to look for:

• Can insights be directly linked to specific strategic priorities or action items?
• Can ownership, timelines, and completion status be tracked for each insight-driven action?
• Does the platform enable leadership to demonstrate how field intelligence influenced clinical development, market access, or HCP education decisions?
• Are there quantitative metrics for insight quality, strategic impact, and time-to-decision?

Why it matters: Medical affairs teams that cannot demonstrate the business impact of their insights investment face budget pressure and strategic marginalisation. Platforms with strong action tracking capabilities transform medical affairs from a cost centre into a measurable strategic asset.